11/120
0.5 / 5 stars
All 120 Win/Lose results shown below
ALLO Roast Me summary
Allogene Therapeutics, Inc. (ALLO). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseALLO / S&P -14.75% / 15.20% |
LoseALLO / S&P ALLO unavailable / 15.00% |
LoseALLO / S&P ALLO unavailable / 50.40% |
| 2026-Q11/3 |
WinALLO / S&P 78.10% / -4.33% |
LoseALLO / S&P ALLO unavailable / 11.30% |
LoseALLO / S&P ALLO unavailable / 27.70% |
| 2025-Q41/3 |
WinALLO / S&P 10.48% / 2.65% |
LoseALLO / S&P -100.00% / 9.00% |
LoseALLO / S&P ALLO unavailable / 13.40% |
| 2025-Q31/3 |
WinALLO / S&P 9.73% / 8.12% |
LoseALLO / S&P -100.00% / 4.61% |
LoseALLO / S&P ALLO unavailable / 13.45% |
| 2025-Q20/3 |
LoseALLO / S&P -22.60% / 10.94% |
LoseALLO / S&P -100.00% / 4.83% |
LoseALLO / S&P ALLO unavailable / 10.63% |
| 2025-Q10/3 |
LoseALLO / S&P -31.46% / -4.27% |
LoseALLO / S&P -100.00% / 4.98% |
LoseALLO / S&P ALLO unavailable / 10.57% |
| 2024-Q40/3 |
LoseALLO / S&P -23.93% / 2.41% |
LoseALLO / S&P -76.84% / 5.25% |
LoseALLO / S&P ALLO unavailable / 6.15% |
| 2024-Q31/3 |
WinALLO / S&P 20.17% / 5.89% |
LoseALLO / S&P -57.00% / 5.89% |
LoseALLO / S&P ALLO unavailable / 6.11% |
| 2024-Q20/3 |
LoseALLO / S&P -47.87% / 4.28% |
LoseALLO / S&P -48.82% / 5.38% |
LoseALLO / S&P ALLO unavailable / 5.12% |
| 2024-Q11/3 |
WinALLO / S&P 39.25% / 10.56% |
LoseALLO / S&P -54.45% / 5.71% |
LoseALLO / S&P ALLO unavailable / 5.59% |
| 2023-Q40/3 |
LoseALLO / S&P 1.26% / 11.69% |
LoseALLO / S&P -39.10% / 6.81% |
LoseALLO / S&P ALLO unavailable / 7.78% |
| 2023-Q30/3 |
LoseALLO / S&P -36.22% / -3.27% |
LoseALLO / S&P -99.87% / 7.52% |
LoseALLO / S&P ALLO unavailable / -5.03% |
| 2023-Q20/3 |
LoseALLO / S&P 0.61% / 8.74% |
LoseALLO / S&P -99.83% / 9.50% |
LoseALLO / S&P ALLO unavailable / -8.57% |
| 2023-Q10/3 |
LoseALLO / S&P -21.46% / 7.50% |
LoseALLO / S&P -99.75% / 10.77% |
LoseALLO / S&P ALLO unavailable / -15.69% |
| 2022-Q40/3 |
LoseALLO / S&P -41.76% / 7.56% |
LoseALLO / S&P -99.86% / 11.88% |
LoseALLO / S&P ALLO unavailable / -17.99% |
| 2022-Q31/3 |
LoseALLO / S&P -5.26% / -4.88% |
WinALLO / S&P 97.32% / 13.47% |
LoseALLO / S&P ALLO unavailable / -1.41% |
| 2022-Q22/3 |
WinALLO / S&P 25.14% / -16.10% |
WinALLO / S&P 97.57% / 13.71% |
LoseALLO / S&P ALLO unavailable / 11.04% |
| 2022-Q11/3 |
LoseALLO / S&P -38.94% / -4.60% |
WinALLO / S&P 97.69% / 15.97% |
LoseALLO / S&P ALLO unavailable / 42.23% |
| 2021-Q40/3 |
LoseALLO / S&P -41.95% / 11.03% |
LoseALLO / S&P ALLO unavailable / 15.00% |
LoseALLO / S&P ALLO unavailable / 96.40% |
| 2021-Q30/3 |
LoseALLO / S&P -1.46% / 0.58% |
LoseALLO / S&P ALLO unavailable / 10.77% |
LoseALLO / S&P ALLO unavailable / 69.42% |
| 2021-Q20/3 |
LoseALLO / S&P -26.12% / 8.55% |
LoseALLO / S&P ALLO unavailable / 6.58% |
LoseALLO / S&P ALLO unavailable / 51.81% |
| 2021-Q11/3 |
WinALLO / S&P 39.86% / 6.17% |
LoseALLO / S&P ALLO unavailable / -1.06% |
LoseALLO / S&P ALLO unavailable / 7.39% |
| 2020-Q40/3 |
LoseALLO / S&P -33.07% / 12.15% |
LoseALLO / S&P ALLO unavailable / -3.72% |
LoseALLO / S&P ALLO unavailable / -33.42% |
| 2020-Q30/3 |
LoseALLO / S&P -11.93% / 8.93% |
LoseALLO / S&P ALLO unavailable / -2.04% |
LoseALLO / S&P ALLO unavailable / -27.10% |
| 2020-Q21/3 |
WinALLO / S&P 120.27% / 20.54% |
LoseALLO / S&P ALLO unavailable / -0.46% |
LoseALLO / S&P ALLO unavailable / -27.11% |
| 2020-Q10/3 |
LoseALLO / S&P -25.17% / -19.60% |
LoseALLO / S&P ALLO unavailable / 3.47% |
LoseALLO / S&P ALLO unavailable / -14.75% |
| 2019-Q40/3 |
LoseALLO / S&P -4.70% / 9.07% |
LoseALLO / S&P ALLO unavailable / 5.36% |
LoseALLO / S&P ALLO unavailable / 2.99% |
| 2019-Q30/3 |
LoseALLO / S&P 1.53% / 1.70% |
LoseALLO / S&P ALLO unavailable / 5.02% |
LoseALLO / S&P ALLO unavailable / 0.21% |
| 2019-Q20/3 |
LoseALLO / S&P -7.13% / 4.30% |
LoseALLO / S&P ALLO unavailable / 6.64% |
LoseALLO / S&P ALLO unavailable / 8.65% |
| 2019-Q10/3 |
LoseALLO / S&P 7.35% / 13.65% |
LoseALLO / S&P ALLO unavailable / 8.12% |
LoseALLO / S&P ALLO unavailable / 14.29% |
| 2018-Q40/3 |
LoseALLO / S&P ALLO unavailable / -13.52% |
LoseALLO / S&P ALLO unavailable / 9.05% |
LoseALLO / S&P ALLO unavailable / 18.23% |
| 2018-Q30/3 |
LoseALLO / S&P ALLO unavailable / 7.71% |
LoseALLO / S&P ALLO unavailable / 10.21% |
LoseALLO / S&P ALLO unavailable / 19.06% |
| 2018-Q20/3 |
LoseALLO / S&P ALLO unavailable / 3.43% |
LoseALLO / S&P ALLO unavailable / 9.03% |
LoseALLO / S&P ALLO unavailable / 14.46% |
| 2018-Q10/3 |
LoseALLO / S&P ALLO unavailable / -0.76% |
LoseALLO / S&P ALLO unavailable / 7.68% |
LoseALLO / S&P ALLO unavailable / 12.46% |
| 2017-Q40/3 |
LoseALLO / S&P ALLO unavailable / 6.64% |
LoseALLO / S&P ALLO unavailable / 7.03% |
LoseALLO / S&P ALLO unavailable / 13.82% |
| 2017-Q30/3 |
LoseALLO / S&P ALLO unavailable / 4.48% |
LoseALLO / S&P ALLO unavailable / 5.68% |
LoseALLO / S&P ALLO unavailable / 17.57% |
| 2017-Q20/3 |
LoseALLO / S&P ALLO unavailable / 3.09% |
LoseALLO / S&P ALLO unavailable / 4.83% |
LoseALLO / S&P ALLO unavailable / 17.74% |
| 2017-Q10/3 |
LoseALLO / S&P ALLO unavailable / 6.07% |
LoseALLO / S&P ALLO unavailable / 3.67% |
LoseALLO / S&P ALLO unavailable / 13.32% |
| 2016-Q40/3 |
LoseALLO / S&P ALLO unavailable / 3.82% |
LoseALLO / S&P ALLO unavailable / 2.09% |
LoseALLO / S&P ALLO unavailable / 7.05% |
| 2016-Q30/3 |
LoseALLO / S&P ALLO unavailable / 3.85% |
LoseALLO / S&P ALLO unavailable / 0.20% |
LoseALLO / S&P ALLO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ALLO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 77.45% | 20.78% |
| Annualized return | 77.45% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ALLO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.91% | 83.14% |
| Annualized return | -39.52% | 12.86% |
10Y · 2018-10-11 to 2026-08-28
| Metric | ALLO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.98% | 319.30% |
| Annualized return | -22.30% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |